GLP-1 Medication Use in Children With Obesity Shows Significant Increase, Study Finds

Fresno Visalia, CA, September 30, 2026 —

A recent study highlighted by ABC30 Fresno indicates a significant rise in the prescription of GLP-1 medications for children diagnosed with obesity. While the overall usage remains infrequent, the trend shows a notable upward trajectory, particularly among younger age groups.

The study, which analyzed data spanning from 2019 to 2026, observed a substantial increase in GLP-1 medication prescriptions for children aged 8 to 11 years who are managing obesity. This demographic, previously prescribed these medications at very low rates, has seen a significant surge in their use over the observed period.

Despite this pronounced increase in rates for specific age groups, the report emphasizes that the total number of prescriptions for GLP-1 medications among all children with obesity remains low when viewed in absolute terms. The research aims to track evolving treatment patterns for pediatric obesity in light of new pharmacological options.

The full scope of the study, including the specific medications analyzed and the methodologies employed to determine the increase in prescription rates, was featured by ABC30 Fresno. The findings suggest a shifting landscape in the management of childhood obesity, with clinicians potentially exploring a wider range of therapeutic interventions. Further details regarding the prevalence of obesity in the studied pediatric population and the clinical context for these prescriptions were not detailed in the summary provided.

The contractor, study authors, or prescribing physicians’ names were not provided. The timeline for data collection and the specific year the study was released were not detailed. The source of the study data beyond its feature by ABC30 Fresno was not specified.

Story summarized from the original created by Danyelle Burke North on abc30.com, see more information here.

Media gallery